Claims

1. Use of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a subject in need thereof in combination with cisplatin, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof and cisplatin are administered together in the treatment period.

2. The use according to claim 1, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate in substantially diastereomerically pure form.

3. The use according to claim 1 or claim 2, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is a mixture of phosphate diastereoisomers.

4. The use according to any one of claims 1 to 3, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is in the form of the free base.

5. The use according to any one of claims 1 to 4, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is to be administered intravenously.

6. The use according to any one of claims 1 to 5, wherein the cancer is a solid tumour.

7. The use according to claim 6, wherein the solid cancer is selected from ovarian cancer, bladder cancer, and biliary tract cancer.

8. The use according to claim 7, wherein the cancer is biliary tract cancer selected from gallbladder cancer, distal bile duct cancer, ampullary cancer, hilar cholangiocarcinoma and intra-hepatic cholangiocarcinoma.

9. The use according to any one of claims 1 to 8, wherein the cancer is relapsed.

10. The use according to any one of claims 1 to 9, wherein the cancer is metastatic.

11. The use according to any one of claims 1 to 10, wherein the cancer is refractory, resistant or partially resistant to the platinum-based anticancer agent.

12. The use according to any one of claims 1 to 10, wherein the cancer is sensitive to the platinum-based anticancer agent.

13. The use according to any one of claims 1 to 12, wherein the dose of NUC-1031 to be administered at each administration event is preferably between 250 mg/m^2 and 1250

mg/m^2 and the dose of the platinum-based anticancer agent to be administered at each administration event is between 10 mg/m^2 and 200 mg/m^2.

14. The use according to any one of claims 1 to 13, wherein administration of the combination provides an intra-cellular $t_{1/2}$ of dFdCTP of more than 10 hours.

15. The use according to any one of claims 1 to 14, wherein administration of the combination provides an intra-cellular $t_{1/2}$ of dFdCTP of more than 18 hours.